Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2021 08:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

BASKING RIDGE, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
February 25, 2021 16:05 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing Conference call begins today at 4:30 p.m. (ET) BASKING RIDGE, N.J., Feb. ...
February 18, 2021 16:05 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
February 17, 2021 13:59 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc. Closes $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules

BASKING RIDGE, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
February 12, 2021 08:15 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules

BASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
January 25, 2021 17:05 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Closes $25.0 Million Private Placement

BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
January 25, 2021 08:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021

BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
January 21, 2021 09:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces $25.0 Million Private Placement

BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
January 19, 2021 08:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

Initiation of the Phase 2b FREEDOM trial represents the next step in development of CLBS16 as a potential breakthrough treatment for the millions of sufferers of CMD in the U.S., most of whom are...
January 06, 2021 08:30 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021

BASKING RIDGE, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...